妖女迷行

全国游泳冠军赛：唐钱婷超女子100米蛙泳亚洲纪录_我的网站

A |     

    Medicine File photo: VCG
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness. 
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source. 
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations. 
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。    新华社深圳4月20日电（记者王浩明）2024全国游泳冠军赛20日进入第二个比赛日，唐钱婷超女子100米蛙泳亚洲纪录，张雨霏女子100米蝶泳夺冠。　　4月20日，唐钱婷在女子100米蛙泳半决赛后庆祝。新华社发（彭志刚摄）　　女子100米蛙泳半决赛上演高光时刻，唐钱婷出发后一路领先，最终游出1分4秒68，超过了该项目的亚洲纪录，这个成绩比她在今年2月卡塔尔世锦赛1分5秒27的夺金成绩提高了0.59秒，这也让唐钱婷成为亚洲第一位在女子100米蛙泳项目上游进1分5秒的选手。　　女子100米蝶泳决赛，奥运冠军张雨霏以56秒36拿下本次比赛个人第二金，余依婷摘得银牌，王一淳获得第三名。　　男子100米蛙泳决赛中，世锦赛三冠王覃海洋以58秒24夺金，孙佳俊获得银牌，董志豪获得铜牌。男子400米个人混合泳决赛中，黄志伟以4分16秒33拿下冠军，领先第二名陈诺超过5秒，李易峰摘得铜牌。

Current article:http://6tcc4x.shuazhepenxingshuaisenqienai.buzz/5ile/20260826/292010.html

Published on:06:21:43